WO2007003675A3 - Experimental neuroinflammation model, method of obtaining same and applications thereof - Google Patents

Experimental neuroinflammation model, method of obtaining same and applications thereof Download PDF

Info

Publication number
WO2007003675A3
WO2007003675A3 PCT/ES2006/000387 ES2006000387W WO2007003675A3 WO 2007003675 A3 WO2007003675 A3 WO 2007003675A3 ES 2006000387 W ES2006000387 W ES 2006000387W WO 2007003675 A3 WO2007003675 A3 WO 2007003675A3
Authority
WO
WIPO (PCT)
Prior art keywords
experimental
neuroinflammation
model
applications
obtaining same
Prior art date
Application number
PCT/ES2006/000387
Other languages
Spanish (es)
French (fr)
Other versions
WO2007003675A2 (en
Inventor
Garcia Ana Maria Fernandez
Aleman Ignacio Torres
Hernandez Silvia Fernandez
Original Assignee
Consejo Superior Investigacion
Garcia Ana Maria Fernandez
Aleman Ignacio Torres
Hernandez Silvia Fernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Garcia Ana Maria Fernandez, Aleman Ignacio Torres, Hernandez Silvia Fernandez filed Critical Consejo Superior Investigacion
Publication of WO2007003675A2 publication Critical patent/WO2007003675A2/en
Publication of WO2007003675A3 publication Critical patent/WO2007003675A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

The invention relates to an experimental neuroinflammation model comprising a transgenic non-human animal, which is characterised in that it expresses, exclusively in astrocytes, a mutated form of calcineurin lacking all or part of the calmodulin binding domain and/or the autoinhibitory domain. Said animal model can be used to study and evaluate the progression of neurodegenerative diseases associated with neuroinflammation and pathological neurological alterations caused by inflammation which lead to neuronal death, as well as to identify anti-inflammatory compounds having an anti-inflammatory effect which is due to astrocytic calcineurin stimulation.
PCT/ES2006/000387 2005-07-06 2006-07-05 Experimental neuroinflammation model, method of obtaining same and applications thereof WO2007003675A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200501650 2005-07-06
ES200501650A ES2289877B1 (en) 2005-07-06 2005-07-06 EXPERIMENTAL MODEL OF NEUROINFLAMACION, PROCEDURE OF OBTAINING AND ITS APPLICATIONS.

Publications (2)

Publication Number Publication Date
WO2007003675A2 WO2007003675A2 (en) 2007-01-11
WO2007003675A3 true WO2007003675A3 (en) 2007-04-26

Family

ID=37604829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2006/000387 WO2007003675A2 (en) 2005-07-06 2006-07-05 Experimental neuroinflammation model, method of obtaining same and applications thereof

Country Status (2)

Country Link
ES (1) ES2289877B1 (en)
WO (1) WO2007003675A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035126A1 (en) * 1995-05-03 1996-11-07 President And Fellows Of Harvard College Assessing calcineurin's role in immunosuppression and neurotoxicity
WO2000009662A1 (en) * 1998-08-17 2000-02-24 The Trustees Of Columbia University In The City Of New York Transgenic nonhuman mammal and uses thereof to identify compounds useful for improving long-term memory
WO2003012093A2 (en) * 2001-07-31 2003-02-13 Genopia Biomedical Gmbh Regulator of calcineurin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035126A1 (en) * 1995-05-03 1996-11-07 President And Fellows Of Harvard College Assessing calcineurin's role in immunosuppression and neurotoxicity
WO2000009662A1 (en) * 1998-08-17 2000-02-24 The Trustees Of Columbia University In The City Of New York Transgenic nonhuman mammal and uses thereof to identify compounds useful for improving long-term memory
WO2003012093A2 (en) * 2001-07-31 2003-02-13 Genopia Biomedical Gmbh Regulator of calcineurin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CONBOY I.M. ET AL.: "calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions", PROC. ACAD. SCI. U.S.A., vol. 96, no. 11, 25 May 1999 (1999-05-25), pages 6324 - 6329, XP003010493 *
KAMINSKA B. ET AL.: "Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses", J. CELL MOL. MED., vol. 8, no. 1, 2004, pages 45 - 58, XP003010495 *
NORRIS C.M. ET AL.: "Calcineurin triggers reactive/inflammatory processes astrocytes and is upregulated in aging and Alzheimer's models", JOURNAL OF NEUROSCIENCE, vol. 25, no. 18, 4 May 2005 (2005-05-04), pages 4649 - 4658, XP003010491 *
PONS S. ET AL.: "Insulin-like growth factor-I stimulates dephosphorylation of ikappa B through the serine phosphatase calcineurin (protein phosphatase 2B)", J. BIOL. CHEM., vol. 275, no. 49, 8 December 2000 (2000-12-08), pages 38620 - 38625, XP003010494 *
SAYEN M.R. ET AL.: "Calcineurin transgenic mice have mitochondrical dysfunction and elevated superoxide production", AM. J. PHYSIOL. CELL PHYSIOL., vol. 284, no. 2, February 2003 (2003-02-01), pages C562 - C570, XP003010492 *
WINDER D.G. ET AL.: "Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin", CELL, vol. 92, no. 1, 9 January 1998 (1998-01-09), pages 25 - 37, XP002916706 *

Also Published As

Publication number Publication date
ES2289877A1 (en) 2008-02-01
ES2289877B1 (en) 2008-12-01
WO2007003675A2 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
EE200600039A (en) Animal Transgenic Model for Modeling Pathological Anxiety, Method for Identifying Compounds Suitable for the Treatment of Pathological Anxiety Diseases or Conditions, and Method for Wfs1 Protein Targeting Against Pathological Anxiety
WO2007142755A3 (en) Purine analogs
ATE540949T1 (en) SUBSTITUTED PTERIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2007109749A3 (en) Methods for preventing and treating amyloidogenic diseases
EA200901486A1 (en) COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
WO2007059108A3 (en) Substituted quinolones and methods of use
DE602006011311D1 (en) IL-10 MUTANT
ZA201201423B (en) Compositions and methods for the control of nematodes and soil borne diseases
ZA200804742B (en) Compounds for the treatment of inflammatory disorders and microbial diseases
IL191637A0 (en) Compounds for the treatment of inflammatory disorders and microbial diseases
ATE482901T1 (en) EQUIPMENT FOR THE PRODUCTION AND/OR ASSEMBLY OF GOODS
ATE510464T1 (en) COMPOSITIONS AND METHODS FOR IMPROVING FUNCTIONAL VASCULAR INTEGRITY, CELL SURVIVAL AND REDUCING APOPTOSIS AFTER AN ISSUE OF BRAIN
WO2009026574A3 (en) Immunogenic compositions and uses thereof
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2008061019A3 (en) Modulators of neuronal regeneration
WO2011041452A3 (en) Mouse model for identifying compounds for the treatment of oxidative stress
WO2007053400A3 (en) Piperidine glycine transporter inhibitors
DE602006016199D1 (en) Needle bearing with a cage and method of making the cage
WO2006039221A3 (en) Cyclopropyl piperidine glycine transporter inhibitors
CN107428652A8 (en) For treating compound, composition and the method for inflammatory disease, degenerative disease and nerve degenerative diseases
DE112007003777A5 (en) Ladder assembly and method of making the same
DE602006004387D1 (en) Process for the preparation of cycloalkanol and / or cycloalkanone
WO2005107469A3 (en) Morpholinyl piperidine glycine transporter inhibitors
CA2837895C (en) Methods of treating or preventing neurological diseases

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06794060

Country of ref document: EP

Kind code of ref document: A2